Skip Navigation
ChemIDplus Lite•Browse•Advanced

Substance Name: Fludarabine phosphate [USAN:USP:BAN]
RN: 75607-67-9
UNII: 1X9VK9O1SC
InChIKey: GIUYCYHIANZCFB-FJFJXFQQSA-N

Molecular Formula

  • C10-H13-F-N5-O7-P

Molecular Weight

  • 365.2127
 

Classification Codes

  • Antimetabolites
  • Antimetabolites, Antineoplastic
  • Antineoplastic
  • Antineoplastic Agents
  • Drug / Therapeutic Agent
  • Human Data
  • Immunologic Factors
  • Immunosuppressive Agents
  • Noxae

Names and Synonyms

Name of Substance

  • Fludarabine phosphate
  • Fludarabine phosphate [USAN:USP:BAN]

Synonyms

  • 2-Fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl)-9H-purin-6-amine
  • 2-Fluoro-ARA AMP
  • 2-Fluoroadenine arabinoside 5'-monophosphate
  • 9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
  • 9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
  • 9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
  • FAMP
  • Fludara
  • Fludarabine 5'-monophosphate
  • Fludarabine phosphate
  • NSC 312887
  • NSC 328002
  • NSC-312887
  • Oforta
  • UNII-1X9VK9O1SC

Systematic Name

  • 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl)-

Registry Numbers

CAS Registry Number

  • 75607-67-9

FDA UNII

  • 1X9VK9O1SC

System Generated Number

  • 0075607679

Structure Descriptors

InChI

InChI=1S/C10H13FN5O7P/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(18)5(17)3(23-9)1-22-24(19,20)21/h2-3,5-6,9,17-18H,1H2,(H2,12,14,15)(H2,19,20,21)/t3-,5-,6+,9-/m1/s1

InChIKey

GIUYCYHIANZCFB-FJFJXFQQSA-N

Smiles

Nc1nc(F)nc2c1ncn2[C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]3O

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
child TDLo intravenous 18750mg/kg/5D (18750mg/kg) BRAIN AND COVERINGS: ENCEPHALITIS

SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE		 Cancer Treatment Reports. Vol. 70, Pg. 1225, 1986.
man TDLo intravenous 11655mg/kg/5D (11655mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE

SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE		 Cancer Treatment Reports. Vol. 70, Pg. 1449, 1986.
man TDLo intravenous 17760mg/kg/5D (17760mg/kg) BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"

BEHAVIORAL: COMA

BRAIN AND COVERINGS: DEMYELINATION		 Cancer Treatment Reports. Vol. 70, Pg. 1225, 1986.
mouse LD50 intravenous 1236mg/kg (1236mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) National Technical Information Service. Vol. PB83-195685,
women LDLo intravenous 14245mg/kg/5D (14245mg/kg) SKIN AND APPENDAGES (SKIN): SWEATING: OTHER

SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE

BEHAVIORAL: EXCITEMENT		 Cancer Treatment Reports. Vol. 70, Pg. 1449, 1986.
women TDLo intravenous 23125mg/kg/5D (23125mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BRAIN AND COVERINGS: ENCEPHALITIS

SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE		 Cancer Treatment Reports. Vol. 70, Pg. 1225, 1986.